Clinical Trials for Gleevec/Sutent-resistant GIST

Main Trials Page | Search Trials | Clinical Trial Site List | Drug Watch List

First-line Trials | Gleevec/Sutent-resistant | All Trials | Recruiting Trials | Preventative (Adjuvant)Treatment Trials

The trials listed below are for Gleevec-resistant GIST (in most cases, Sutent-resistant as well). Click on the hyperlinks for more details about each trial. You will also have the opportunity to access trial site data later. Trials are sorted so that trials that are only for GIST appear first. Trials are also sorted so that trials in later phases sort higher on the list. Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

 
Currently showing 20 of 57 trials
Page 1 of 3 | Next | Last

Nilotinib or Imatinib
Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)
Phase:  3
Category:  
KIT/PDGFRA inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Site name unknown Monteria Monteria Colombia
Site name unknown Buenos Aires Buenos Aires Argentina
Site name unknown Belo Horizonte Belo Horizonte Brazil
Site name unknown Porto Alegre Porto Alegre Brazil
Site name unknown Barretos Barretos Brazil
Site name unknown Santo Andre Santo Andre Brazil
Site name unknown Jau Jau Brazil
Site name unknown Jatal Jatal Brazil
Site name unknown Rio de Janeiro Rio de Janeiro Brazil
Site name unknown Medellin Medellin Colombia
Site name unknown Hwasun-gun Hwasun-gun Republic of Korea
Site name unknown Seoul Seoul Republic of Korea
Site name unknown Daegu Daugu Republic of Korea
Site name unknown Panama Panama Panama
Site name unknown Bangkok Bankok Thailand
Khon Kaen University Khon Kaen Thailand
Prince of Songkla University Songkla Thailand
Site name unknown Caracas Caracas Venezuela


Sunitinib
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
Phase:  3
Category:  
KIT/PDGFRA inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Site name unknown Delhi New Delhi Delhi India
Site name unknown Mumbai Mumbai Mumbai India


BIIB021 (CNF2024)
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment
Phase:  2
Category:  
HSP90 inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Memorial Sloan-Kettering Cancer Center New York NY USA
Mayo Clinic, Rochester Rochester MN USA


Nilotinib
Nilotinib in Advanced GIST
Phase:  2
Category:  
KIT/PDGFRA inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Fox Chase Cancer Center Philadelphia PA USA


Nilotinib
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
Phase:  2
Category:  
KIT/PDGFRA inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Site name unknown, Tel Aviv Tel Aviv Israel
Site name unknown, Tel Hashomer Tel Hashomer Israel
Site name unknown Jerusalem Jerusalem Israel


Regorafenib
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Phase:  2
Category:  
KIT/PDGFRA inhibitor VEGFR inhibitor (TKI)
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA


Sorafenib (Nexavar, BAY 43-9006)
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
Phase:  2
Category:  
KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI) + RAF inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
University of Chicago Chicago IL USA
Memorial Sloan-Kettering Cancer Center New York NY USA
City of Hope Duarte CA USA
Illinois CancerCare Peoria IL USA
Cancer Care Specialists Decatur IL USA
USC-Norris Cancer Center Los Angeles CA USA
UC-Davis Sacramento CA USA
Central Illinois Hem/Onc Springfield IL USA
University of Michigan Ann Arbor MI USA
Medical College of Wisconsin Milwaukee WI USA


STA-9090
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
Phase:  2
Category:  
HSP90 inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA


Sunitinib
Evaluation of Patients With Bulky GIST Using Sunitinib
Phase:  2
Category:  
KIT/PDGFRA inhibitor+ VEGF inhibitor (antibody)
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
UAB Comprehensive Cancer Center Birmingham AL USA


Nilotinib
Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST)
Phase:  
Category:  
KIT/PDGFRA inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Asan Medical centre Seoul Republic of Korea


Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
Phase:  4
Category:  
VEGFR inhibitor (TKI)
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
University Medical Center Nijmegen st Raboud Nijmegen Gelderland Netherlands


Dasatinib (BMS-354825)
Trial of Dasatinib in Advanced Sarcomas
Phase:  2
Category:  
KIT/PDGFRA inhibitor + SRC inhibitor
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Arkansas Children's Hospital Little Rock AR USA
Stanford Cancer Center Palo Alto CA USA
City of Hope Duarte CA USA
Cedars-Sinai Outpatient Cancer Center Los Angeles CA USA
Washington Cancer Institute Washington DC USA
Emory Winship Cancer Institute Atlanta GA USA
Kootenai Cancer Center Coeur d'Alene ID USA
Oncology Specialists, Park Ridge Park Ridge IL USA
Indiana University Simon Cancer Center Indianapolis IN USA
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Massachusetts General Hospital Boston MA USA
Dana Farber Cancer Institute Boston MA USA
University of Michigan Ann Arbor MI USA
Nebraska Methodist Hospital Omaha NB USA
Pennsylvania Oncology Hematology Associates Philadelphia PA USA
Fox Chase Cancer Center Philadelphia PA USA
University of Pittsburgh Cancer Institute Pittsburgh PA USA
MD Anderson Cancer Center Houston TX USA
Sarcoma Oncology Center Santa Monica CA USA
University of Iowa Hospitals and Clinics Iowa City IA USA


Everolimus
Treatment of Patients With RAD001 Who Have Progressive Sarcoma
Phase:  2
Category:  
mTOR inhibitor
Conditions:  
 Sarcoma
Site
City
State
Country
Site name unknown, Berlin Berlin Germany
Site name unknown, Munchen Munchen Germany
Site name unknown, Dusseldorf Dusseldorf Germany
Site name unknown, Mannheim 68135 Mannheim Germany
Site name unknown, Milan Milan Italy


Doxorubicin + Flavopiridol
Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
Phase:  1
Category:  
Transcription inhibitor + Chemotherapy
Conditions:  
 Gastrointestinal Stromal Tumor Sarcoma
Site
City
State
Country
Memorial Sloan-Kettering Cancer Center New York NY USA


Imatinib + IL-2
Imatinib + IL-2
Phase:  1
Category:  
KIT inhibitor + Immune stimulate
NCT #:
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Institut Gustave-Roussy Villejuif Cedex France


Multi-bacteria vaccine (MBV)
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.
Phase:  1
Category:  
Immune stimulate
Conditions:  
 Gastrointestinal Stromal Tumor
Site
City
State
Country
Krankenhaus Nordwest Frankfurt Germany


PLX3397
Safety Study of PLX108-01 in Patients With Solid Tumors
Phase:  1
Category:  
KIT inhibitor
Conditions:  
 Solid Tumors
Site
City
State
Country
TGen Clinical Research Services Scottsdale AZ USA
Evergreen Hematology and Oncology Spokane WA USA


SF1126
A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors
Phase:  1
Category:  
PI3K inhibitor
Conditions:  
 Solid Tumors
Site
City
State
Country
TGen Clinical Research Services Scottsdale AZ USA
Indiana University Simon Cancer Center Indianapolis IN USA
Arizona Cancer Center Tucson AZ USA
Emory Winship Cancer Institute Atlanta GA USA


AUY922
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.
Phase:  1
Category:  
HSP90 inhibitor
Conditions:  
 Solid Tumors
Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
Washington University School of Medicine St. Louis MO USA
Nevada Cancer Institute Las Vegas NV USA
David Geffen School of Medicine at UCLA Los Angeles CA USA
Medical College of Georgia Augusta GA USA
Cancer Therapy and Research Center San Antonio TX USA
MD Anderson Cancer Center Houston TX USA
Site Name unknown, Bellinzona Bellinzona Switzerland


BGT226
A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Phase:  1
Category:  
mTOR inhibitor PI3K inhibitor
Conditions:  
 Solid Tumors
Site
City
State
Country
Nevada Cancer Institute Las Vegas NV USA
Dana Farber Cancer Institute Boston MA USA
Massachusetts General Hospital Boston MA USA
Cancer Therapy and Research Center San Antonio TX USA
Hospital Vall d'Hebron Barcelona Spain
Princess Margaret Hospital Toronto ON Canada


 
20 of 
57 Trials Found Page 1 of 3 | Next | Last